Gastrin and Somatostatin Levels in Patients with Gastric Cancer

M. Pawlikowski; D. Cieślak; J. Berner; K. Rybiński; A. Lewiński; S. M. Webb

doi:10.1055/s-2007-1009158

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 1989; 21(2): 89-91
DOI: 10.1055/s-2007-1009158

Clinical

Gastrin and Somatostatin Levels in Patients with Gastric Cancer

M. Pawlikowski¹ , D. Cieślak¹ , J. Berner³ , K. Rybiński² , A. Lewiński¹ , S. M. Webb⁴

¹Department of Experimental Endocrinology and Hormone Diagnostics
²Department of Endocrine Surgery, Institute of Endocrinology
³Chair of Oncology, School of Medicine of Lodz, Lodz, Poland
⁴Department of Endocrinology, Hospital Sant Pau, Autonomous University, Barcelona, Spain

Abstract

als PDF herunterladen

Summary

Gastrin and somatostatin-like immunoreactivity (SLI) levels were studied by means of radioimmunoassay in peripheral venous blood of healthy volunteers and patients suffering from gastric adenocarcinoma or duodenal and gastric ulcers. Gastrin and SLI levels were also evaluated in patients in blood drawn from gastric veins during surgery. The elevations of gastrin and SLI levels were found in patients with gastric cancer as compared with healthy people and patients suffering from ulcers. The impairment of the negative feedback between gastrin and somatostatin secretions in patients with gastric cancer was suggested.

Key-Words

Gastrin - Somatostatin - Gastric Cancer

PDF (328 kb)